Genesis Automation Secures €10 Million to Fund Expansion

January 11, 2022

Financing Will Support U.S. Commercialization and Broaden the Company’s Product Offering for Complete Clinical Traceability  

St. Petersburg, FL (January 11, 2022) – Genesis Automation today announced that it has secured €10 million in Growth Debt financing from IPF Partners, a leading alternative financing provider focused on the healthcare sector. 

This financing allows Genesis to continue its investment in its market leading platform, add to its rich product suite and continue to commercialize across key geographies, Ireland, UK, and US.  The announcement follows significant traction across the UK and US markets, with Genesis signing a multi-year agreement with the National Health Services Scotland to deliver complete clinical traceability across Scotland as well as signing a significant partnership agreement with a major US medical device manufacturer to deliver Genesis to their customer base in the US market.   

“We started our relationship with Genesis in 2015 and have seen the company develop and strengthen its position significantly. This agreement underpins our belief in Genesis’ vision to help every hospital improve financial and patient health by taking a more intelligent and automated approach to clinical supply chain management,” said Raeto Guler, Partner at IPF Partners.   

Speaking about the agreement, Ian Mc Dermott, Chief Financial Officer of Genesis Automation, said, “IPF have been a hugely supportive partner of Genesis and have helped us navigate through challenges over the last number of years. Their knowledge of the healthcare sector as well as innovate funding structures aligned with our growth profile has enabled us to expand across both existing markets and into new territories. We are delighted to have IPF as partners and look forward to continuing our partnership as we look to bring new products and innovations to the market.”  

About Genesis 

Genesis is a clinical traceability solution that brings new automation and intelligence to the management of care-critical supplies at every point in The Clinical Supply Lifecycle™. Capable of managing the lowest cost consumable to the highest cost implant, Genesis enables true enterprise-grade traceability in the clinical environment. Set apart by its unique ability to affect every part of the revenue cycle while radically improving the lives of clinicians and their patients, Genesis empowers the hospital system to transform its clinical supply chain into a pillar of value maximization. To learn more, visit 

About IPF 

IPF Partners, based in Luxembourg, is a leading alternative financing provider focused on the healthcare sector. IPF invests directly in emerging pharma/biotech, MedTech and diagnostics companies. Founded in 2011 by a seasoned multi-disciplinary team combining over fifty years of finance and investment and over thirty years of healthcare experience, IPF has developed a unique business model using the team’s specialist sector knowledge to provide bespoke, long-term financing. For more information visit